<DOC>
	<DOCNO>NCT02597309</DOCNO>
	<brief_summary>The aim study evaluate effect add SGLT-2 inhibitor ( namely Canagliflozin ) dose U-500 insulin require achieve glycemic control patient type 2 diabetes . We hypothesize add Canagliflozin patient treat U-500 insulin may result significant reduction insulin dose due improve insulin sensitivity weight loss .</brief_summary>
	<brief_title>The Effect add-on Canagliflozin Patients With Type 2 Diabetes Treated With U-500 Insulin</brief_title>
	<detailed_description>Insulin resistance one main cause type 2 diabetes . Continuation insulin resistance may lead failure multiple oral antihyperglycemic medication achieve glycemic control requirement escalade dos insulin . On contrary , reduction glucose toxicity weight loss improve insulin sensitivity may result substantial reduction insulin dose % A1C . U-500 insulin fastest-growing prescribed insulin US due increase prevalence severe obesity extreme insulin resistance . Patients require high insulin dos ≥200 units/day typical candidate U-500 insulin . However , patient high dos insulin rarely achieve target glycemic control . Sodium-glucose co-transporter-2 ( SGLT2 ) inhibitors new antihyperglycemic medication approve treatment type 2 diabetes . Adding SGLT-2 inhibitor antihyperglycemic medication show reduce glucose toxicity , improve insulin sensitivity reduce body weight . Consequently , daily insulin dose may reduce without compromise glycemic control . Canagliflozin sodium-glucose transporter subtype 2 ( SGLT2 ) inhibitor approve FDA treatment Type 2 diabetes March , 2013 . Canagliflozin , dose 100mg 300mg daily , improve blood sugar control novel mechanism cause kidney block reabsorption 50-80 gram glucose . Canagliflozin lower renal threshold glycosuria cause excess glucose excreted urine . The aim study evaluate effect add SGLT-2 inhibitor ( namely Canagliflozin ) dose U-500 insulin require achieve glycemic control patient type 2 diabetes . We hypothesize add Canagliflozin patient treat U-500 insulin may result significant reduction insulin dose due improve insulin sensitivity weight loss . This double-blind , randomize , placebo-controlled clinical trial . Eligible subject patient type 2 diabetes treat ≥200 unit per day U-500 insulin without antihyperglycemic medication . Participants randomize 1:1 ratio one follow 2 study arm . I . Intervention Group : Subjects group take canagliflozin addition regular U-500 insulin dose antihyperglycemic medication . Canagliflozin dose titrate 2 week 100 mg daily 300 mg daily . This dose continue 22 week . II . Control Group : Subjects group take match placebo addition regular U-500 insulin dose antihyperglycemic medication 2 week another matched-placebo 22 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Subject type 2 diabetes Subject manage ≥200 unit U500 insulin plus minus stable dose oral antihyperglycemic medication least 3 month ( dose oral antihyperglycemic medication remain stable intervention ) Subject male nonpregnant nonlactating female Subject BMI &gt; 25 kg/m2 Subject A1C &gt; 7 % Subject serum potassium 55.5 mEq/L If subject chronic medication antihypertensive , lipidlowering medication , thyroid medication hormonal therapy , dose medication stable least three month prior screen visit . These medication change intervention period unless mandatory Subject history renal disease ( serum creatinine &gt; 1.5mg/dL GFR &lt; 60 mL/min/1.73 m2 ) . Subject history recurrent urinary tract infection Subject history urinary incontinence Subject history prostate hypertrophy Subject history cancer bladder cancer prostate Subject history hematuria Subject use corticosteroid treatment , except inhaled topical steroid Subject active malignancy ( exclude follow dermal malignancy : basal cell carcinoma , squamous cell carcinoma , carcinoma insitu cervix ) . Subject state he/she recent cardiovascular event ( e.g . myocardial infarction , stroke ) ≤ six month prior screen visit ; state he/she history congestive heart failure . Subject hepatic failure status post organ transplant Subject chronic , contagious infectious disease Subject blood clot bleeding disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>